Fig. 5.

A subject with multicentric Castleman disease (MCD) with lesions in the axillary, neck, and abdomen is shown over the course of 10 months. a indicated the initial lesions seen in PET before treatment. b was taken after 4 months from the initial scan, and a decrease of lesions in the axillary, neck, and abdomen is seen. However, the disease seemed to reappear in the axillary and cervical lesions despite treatment as visualized in c, which was taken 6 months after the scan for b. Total lesion glycolysis (TLG) was calculated to be 365.9, 204.5, and 601.6 for a–c, respectively. TLG was calculated by multiplying the metabolic volume with FDG uptake segmented by fixed threshold methods at 41% of maximum SUV in the volume of interest (VOI) [75] by the mean standardized uptake value (SUVmean) and then summing all the intensity-volume product values from all lesions